Asia-Pacific markets open mixed after record global stock rally amid Venezuela tensions

Asia-Pacific markets open mixed after record global stock rally amid Venezuela tensions


19 November 2025, China, Shanghai: Boats sail past downtown Shanghai on the Huangpu River. The tallest building on the skyline is the Shanghai Tower (rear).

Bernd von Jutrczenka | Picture Alliance | Getty Images

Asia-Pacific markets opened mixed Tuesday, building on a record-breaking rally in global stocks as investors continued to assess ongoing geopolitical tensions following the U.S.′ attack on Venezuela and capture of ousted leader Nicolas Maduro.

Japan’s benchmark Nikkei 225 index rose 1.12%, while the Topix jumped 1.48% to a record high. South Korea’s Kospi lost 0.85%, while and small-cap Kosdaq inched 0.09% higher.

Australia’s ASX/S&P 200 slid 0.42%.

Hong Kong’s Hang Seng Index added 0.7%, while the mainland CSI 300 traded flat.

U.S. equity futures were flat in early Asian hours.

Overnight in the U.S., stocks rose even after the U.S.′ attack on Venezuela, as crude oil prices advanced and investors bet the action would not lead to broader geopolitical conflict.

The Dow Jones Industrial Average gained 594.79 points, or 1.23%, to close at 48,977.18. The 30-stock index also hit a new all-time high in the session. The S&P 500 advanced 0.64% and ended at 6,902.05. The Nasdaq Composite added 0.69%, settling at 23,395.82.

— CNBC’s Liz Napolitano, Fred Imbert and Sean Conlon contributed to this report.



Source

Investors are misreading news about the Iran war, analysts say as markets whipsaw
World

Investors are misreading news about the Iran war, analysts say as markets whipsaw

An Iranian flag flutters as a woman walks past damaged buildings amid a 10-day ceasefire between Lebanon and Israel, in the southern suburbs of Beirut, Lebanon, April 20, 2026. Marko Djurica | Reuters “Complacent” investors risk getting wrong-footed as they continue to misread developments in the Iran war, analysts said after markets reacted to the […]

Read More
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to  billion
World

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday. Lilly will pay $3.25 billion upfront, and the remaining payments are contingent upon clinical, […]

Read More
USA Rare Earth to buy Brazil’s Serra Verde for .8 billion to build supply outside Asia
World

USA Rare Earth to buy Brazil’s Serra Verde for $2.8 billion to build supply outside Asia

USA Rare Earth has announced plans to buy Brazilian rare earths miner Serra Verde in a deal worth $2.8 billion in cash and shares, as it seeks to challenge China’s dominance of the supply chain. The Oklahoma-headquartered company said it will pay $300 million in cash and $126.9 million in its own newly issued stock […]

Read More